Their own forecast for the rebate for 2024 $4.6m...
Even if you were to reverse their own impairment of $4.5m - the forecast for the rebate is still only ~$9m for FY2024.
It is uncertain when they'll actually receive the 24 rebate - but it's quite possible a raise is required before this time.
The reason they've brought Azer-Cel to Aus is to enable more of their spend to qualify for the rebate - i.e. you can't just run a trial in the US and claim the Aus govt's tax rebate for development costs.
If Azer-Cel was launched locally and then expanded to the US, it's likely the entire clinical spend would have qualified for the rebate. Read the guidelines.
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
1.3¢ |
Change
0.002(18.2%) |
Mkt cap ! $97.07M | |||
| Open | High | Low | Value | Volume |
| 1.2¢ | 1.4¢ | 1.1¢ | $625.7K | 50.56M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 20 | 5795292 | 1.2¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 1.3¢ | 3258567 | 9 |
View Market Depth
| Last trade - 16.10pm 27/06/2025 (20 minute delay) ? |
| IMU (ASX) Chart |